Advisor at the intersection of clinical neuroscience, neurotechnology, and medical device regulation.
35+ years in translational biomedical research, clinical neurodiagnostics, and regulatory science. I help neurotech and medical-device companies, investors, and boards assess three things that usually fall to three different people:
whether the science holds,
whether the clinical evidence will support the claim,
how a regulator will actually read the submission.
Selective advisory, due diligence, and scientific board engagements.